Welcome to LookChem.com Sign In|Join Free
  • or
(1E,4E)-8-chloro-4-((diMethylaMino)Methylene)-1-(2-fluoro-6-Methoxyphenyl)-3,4-dihydrobenzo[c]azepin-5-one is a synthetic organic compound with a complex molecular structure. It features a chloro group, a dimethylamino group, a methylene group, and a fluoro-6-methoxyphenyl group, all attached to a dihydrobenzo[c]azepin-5-one core. (1E,4E)-8-chloro-4-((diMethylaMino)Methylene)-1-(2-fluoro-6-Methoxyphenyl)-3,4-dihydrobenzo[c]azepin-5-one may have potential pharmaceutical applications, as similar structures have been studied for their potential as antipsychotic and antidepressant drugs. The presence of a chlorine atom in the structure may also confer unique chemical properties, making it of interest for further study in medicinal chemistry and pharmacology.

869367-33-9

Post Buying Request

869367-33-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

869367-33-9 Usage

Uses

Used in Pharmaceutical Industry:
(1E,4E)-8-chloro-4-((diMethylaMino)Methylene)-1-(2-fluoro-6-Methoxyphenyl)-3,4-dihydrobenzo[c]azepin-5-one is used as a potential candidate for the development of antipsychotic and antidepressant drugs due to its structural similarities with compounds that have been investigated for these therapeutic applications. Its unique chemical properties, including the presence of a chlorine atom, may contribute to its effectiveness in treating mental health disorders.

Check Digit Verification of cas no

The CAS Registry Mumber 869367-33-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,9,3,6 and 7 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 869367-33:
(8*8)+(7*6)+(6*9)+(5*3)+(4*6)+(3*7)+(2*3)+(1*3)=229
229 % 10 = 9
So 869367-33-9 is a valid CAS Registry Number.

869367-33-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name (4E)-8-chloro-4-(dimethylaminomethylene)-1-(2-fluoro-6-methoxy-ph enyl)-3H-2-benzazepin-5-one

1.2 Other means of identification

Product number -
Other names 3H-2-Benzazepine,4,5-dibromo-8-chloro-4,5-dihydro-1-phenyl

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:869367-33-9 SDS

869367-33-9Relevant academic research and scientific papers

Small molecule with Aurora kinase degradation activity, preparation method and application thereof

-

, (2020/12/30)

The invention discloses a small molecule with Aurora kinase degradation activity, a preparation method and application thereof. According to the invention, 12 Aurora-A protein degradation agents basedon a PROTAC technology are obtained by using three E3 u

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors

Sells, Todd B.,Chau, Ryan,Ecsedy, Jeffrey A.,Gershman, Rachel E.,Hoar, Kara,Huck, Jessica,Janowick, David A.,Kadambi, Vivek J.,Leroy, Patrick J.,Stirling, Matthew,Stroud, Stephen G.,Vos, Tricia J.,Weatherhead, Gabriel S.,Wysong, Deborah R.,Zhang, Mengkun,Balani, Suresh K.,Bolen, Joseph B.,Manfredi, Mark G.,Claiborne, Christopher F.

, p. 630 - 634 (2015/06/30)

The Aurora kinases are essential for cell mitosis, and the dysregulation of Aurora A and B have been linked to the etiology of human cancers. Investigational agents MLN8054 (8) and alisertib (MLN8237, 10) have been identified as high affinity, selective,

CRYSTALLINE FORMS OF SODIUM 4-{[9-CHLORO-7-(2-FLUORO-6--METHOXYPHENYL)-5H -PYRIMIDO[5,4-D][2]BENZAZEPIN-2YL]AMINO}-2-METHOXYBENZOATE

-

, (2011/09/19)

The present invention is directed to a compound of formula (Z): or a crystalline form thereof, or a solvate thereof; to a solid pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 869367-33-9